Smart + Strong.
All Rights Reserved.
Smart + Strong®
is a registered trademark of CDM Publishing, LLC.
New analyses show that the long-acting injections may be even more effective than previously reported.
Previous studies of the association between tenofovir and the coronavirus have yielded mixed results.
The U.S. government clarified that health insurers must cover PrEP and the associated doctor visits and tests. Here’s why.
Awareness of the HIV prevention pills don’t match their use.
HIV clinics could lose over $100 million each year—notably those serving Black, brown, queer and Southern communities.
Previous studies of the association between tenofovir and COVID-19 outcomes in people with HIV have yielded mixed results.
The availability of multiple, low-cost generic versions of PrEP should be good news for access. But will it be?
The agency will accept public comment on the proposed guidelines during two webinars on May 24 and 25.
Several formulations of generic Truvada are now available at a lower cost.
The HIV prevention bill now heads to the Oregon Senate. Here’s why better PrEP and PEP access could help Latinos and Black Americans.
Study also finds that trans girls are more likely to receive gender-affirming care than trans boys.
Six months after starting PrEP, less than half of women who inject drugs were still taking it, but those who did were satisfied with it.
Plus, nearly a third of people already taking Truvada for PrEP switched to the new combination pill.
An East Harlem HIV prevention campaign focuses on Black and Latino New Yorkers at higher risk.
The Department of Health and Human Services has updated its HIV treatment and prevention guidelines for pregnant people and their infants.
You have been inactive for 60 minutes and will be logged out in . Any updates not saved will be lost.
Click here to log back in.